文献速递艾滋病与性传播感染

多替拉韦与依非韦伦抗逆转录病毒治疗主要不良心血管事件风险:南非常规去标识数据模拟目标试验

Risk of Major Adverse Cardiovascular Events With Dolutegravir Versus Efavirenz-Based Antiretroviral Therapy: Emulated Target Trials Using Routine, De-identified Data From South Africa.
PubMed 文献 · Clin Infect Dis · 2026-01-01

本研究利用南非管理医疗组织去标识数据,模拟目标试验比较替诺福韦/拉米夫定/多替拉韦(TLD)与替诺福韦/恩曲他滨/依非韦伦(TEE)启动或转换后3年主要不良心血管事件(MACE)风险。启动队列7310人,TLD组3年MACE风险0.78% vs TEE组1.03%(RR 0.75,95%CI 0.31-1.30);结论:南非HIV感染者中未发现TLD增加MACE风险。

要点

  • 南非HIV感染者启动TLD与TEE相比,3年MACE风险无显著差异。
  • 从TEE转换为TLD者与继续TEE者相比,MACE风险亦无显著差异。
  • 需更大样本或更长随访确认罕见心血管事件风险。

核心结论

  • 在南非HIV感染者中,未发现基于多替拉韦的TLD方案相比基于依非韦伦的TEE方案增加主要不良心血管事件风险。

研究设计与样本

  • 启动队列采用逆概率治疗加权 pooled logistic 回归和自举置信区间比较3年MACE风险。
  • 转换队列采用类似方法进行44个月度序贯模拟试验,比较转换为TLD与继续TEE者的MACE风险。

临床怎么用

  • 对于南非或其他类似资源有限地区的HIV感染者,启动或转换为TLD方案时无需过度担忧MACE风险增加。
  • 临床决策仍应综合评估个体心血管风险因素和药物可及性。

局限性

  • 观察性数据模拟目标试验可能存在未测量混杂。
  • MACE事件数较少,置信区间较宽,不能排除中等效应。
  • 随访时间相对较短,中位21-25个月,长期风险未评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Integrase inhibitors, including dolutegravir, may increase risk of major adverse cardiovascular events (MACEs). However, limited data exists from low- and middle-income countries, where tenofovir disoproxil fumarate, lamivudine, and dolutegravir (TLD) has largely replaced tenofovir disoproxil fumarate, emtricitabine, and efavirenz (TEE). METHODS: We used de-identified data from a South African managed healthcare organization from people with HIV (PWH) without cardiovascular disease, who either initiated TEE or TLD between April 2020 and Dec 2023 (initiation cohort) or were receiving TEE in April 2020 and eligible for TLD (transition cohort). In the initiation cohort, we emulated a target trial using pooled logistic regression models with inverse probability of treatment weights and bootstrapped CIs to compare estimated 3-year MACE risk between TLD versus TEE. In the transition cohort, we used similar methods in 44 emulated monthly sequential trials, comparing MACE risk in people transitioned to TLD with those remaining on TEE. RESULTS: In the initiation cohort, 7310 PWH initiated TLD (n = 3711) or TEE (n = 3599). Median follow-up was 21 months (IQR 10-33), with 18 MACEs with TLD (3-year risk 0.78%, 95% CI .38-1.11) and 28 with TEE (3-year risk 1.03%, 0.63-1.55; RR 0.75, 0.31-1.30; RD -0.25, -0.94-0.24). In the transition cohort, 22 338 people contributed to 2837 person-trials with TLD and 706 615 with TEE. Median follow-up was 25 months (14-36), with 19 MACEs with TLD (3-year risk 0.97%, 0.52-1.62) and 5420 with TEE (3-year risk 1.17%, 0.99-1.37; RR 0.83, 0.45-1.39; RD -0.20, -0.66-0.44). CONCLUSIONS: Among PWH in South Africa, we found no increased MACE with TLD.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Dorward J, Masombuka X, Lewis L, et al. Risk of Major Adverse Cardiovascular Events With Dolutegravir Versus Efavirenz-Based Antiretroviral Therapy: Emulated Target Trials Using Routine, De-identified Data From South Africa. Clin Infect Dis. 2026. PMID: 41787927. doi:10.1093/cid/ciag155

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。